Lexaria Bioscience Corp. (LEXX)
2.97
+0.20
(+7.22%)
USD |
NASDAQ |
Oct 06, 14:20
Lexaria Bioscience Free Cash Flow : -7.527M for May 31, 2026
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| May 31, 2026 | -7.527M |
| February 28, 2026 | -9.470M |
| November 30, 2025 | -8.775M |
| August 31, 2025 | -10.55M |
| May 31, 2025 | -9.854M |
| February 28, 2025 | -7.539M |
| November 30, 2024 | -6.690M |
| August 31, 2024 | -5.148M |
| May 31, 2024 | |
| February 29, 2024 | |
| November 30, 2023 | |
| May 31, 2023 | -5.587M |
| February 28, 2023 | -5.065M |
| November 30, 2022 | -5.116M |
| August 31, 2022 | -5.060M |
| May 31, 2022 | -4.913M |
| February 28, 2022 | -4.854M |
| November 30, 2021 | -4.470M |
| August 31, 2021 | -4.069M |
| May 31, 2021 | -3.643M |
| February 28, 2021 | -3.089M |
| November 30, 2020 | -2.916M |
| August 31, 2020 | -2.652M |
| May 31, 2020 | -2.809M |
| February 29, 2020 | -3.465M |
| Date | Value |
|---|---|
| November 30, 2019 | -3.644M |
| August 31, 2019 | -3.815M |
| May 31, 2019 | -3.868M |
| February 28, 2019 | -3.117M |
| November 30, 2018 | -2.782M |
| August 31, 2018 | -2.568M |
| May 31, 2018 | -1.821M |
| February 28, 2018 | -1.834M |
| November 30, 2017 | -1.721M |
| August 31, 2017 | -1.317M |
| May 31, 2017 | -1.468M |
| February 28, 2017 | -0.9729M |
| November 30, 2016 | -0.5713M |
| August 31, 2016 | -0.6687M |
| May 31, 2016 | -0.9801M |
| February 29, 2016 | -1.298M |
| November 30, 2015 | -1.577M |
| August 31, 2015 | -1.538M |
| May 31, 2015 | |
| February 28, 2015 | |
| November 30, 2014 | |
| July 31, 2014 | -0.4211M |
| April 30, 2014 | -0.1381M |
| January 31, 2014 | 0.0871M |
| October 31, 2013 | 0.2294M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Target Group, Inc. (Canada) | -1.168M |
| InMed Pharmaceuticals, Inc. | -8.628M |
| XORTX Therapeutics, Inc. | -5.239M |
| NervGen Pharma Corp. | -18.43M |
| Milestone Pharmaceuticals, Inc. | -61.10M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -1.635M |
| Cash from Investing (Quarterly) | -0.0271M |
| Free Cash Flow Per Share (Quarterly) | -1.005 |
| Free Cash Flow to Equity (Quarterly) | -1.654M |
| Free Cash Flow to Firm (Quarterly) | -1.661M |
| Free Cash Flow Yield | -168.6% |